Astrazeneca (AZN) Total Liabilities (2009 - 2026)

Astrazeneca (AZN) has reported Total Liabilities for 18 consecutive years, with -$66.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities fell 2.32% year-over-year to -$66.6 billion; the TTM figure through Mar 2026 stood at -$66.6 billion (down 2.32% YoY), while the FY2025 annual figure was -$65.4 billion, down 203.47% from the prior year.
• Total Liabilities came in at -$66.6 billion for Q1 2026 at Astrazeneca, down from -$65.4 billion in the prior quarter.
• The five-year high for Total Liabilities was $63.2 billion in Q4 2024, with the low at -$68.5 billion in Q3 2025.
• Average Total Liabilities over 5 years is -$41.5 billion, with a median of -$63.9 billion recorded in 2022.
• Across the five-year window, Total Liabilities gained 12.3% in 2022 and sank 203.47% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $59.4 billion in 2022, then gained by 4.25% to $62.0 billion in 2023, then rose by 1.95% to $63.2 billion in 2024, then tumbled by 203.47% to -$65.4 billion in 2025, then dropped by 1.95% to -$66.6 billion in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered -$66.6 billion, -$65.4 billion, and -$68.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.